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Abstract Several lines of evidence suggest a functional
interaction between central nicotinic and endocannabinoid
systems. Furthermore, type 1 cannabinoid receptor (CB1R)
antagonism is evaluated as antismoking therapy, and
nicotine usage can be an important confound in positron
emission tomography (PET) imaging studies of the CB1R.
We evaluated CB1R binding in the rat brain using the PET
radioligand [18F]MK-9470 after chronic administration of
nicotine. Twelve female Wistar rats were scanned at
baseline and after chronic administration of either nicotine
(1 mg/kg; 2 weeks daily intraperitoneal (IP)) or saline as
control. In vivo micro-PET images of CB1R binding were
anatomically standardized and analyzed by voxel-based
statistical parametric mapping and a predefined volume-of-
interest approach. We did not observe changes in [18F]MK-
9470 binding (pheight<0.001 level; uncorrected) on a group
basis in either condition. Only at a less stringent threshold
of pheight<0.005 (uncorrected) was a modest increase
observed in tracer binding in the cerebellum for nicotine
(peak voxel value + 6.8%, pcluster=0.002 corrected). In
conclusion, chronic IP administration of nicotine does not
produce major cerebral changes in CB1R binding of [18F]
MK-9470 in the rat. These results also suggest that chronic
nicotine usage is unlikely to interfere with human PET
imaging using this radioligand.
Keywords Nicotine . Type 1 cannabinoid receptor .
Micro-PET. Rat brain
Introduction
Nicotine is considered to be the primary psychoactive
compound of tobacco smoke that establishes and maintains
tobacco dependence. Several lines of evidence suggest that
there may be a functional interaction between the central
nicotinic and endocannabinoid systems (ECS; Castane et al.
2005). The ECS is involved in the brain reward processing
circuitry which becomes activated in drug addiction. Release
of endocannabinoids in the ventral tegmental area (VTA), an
important component of the reward and mesocorticolimbic
dopaminergic circuitry, is assumed to play a role in inducing
the rewarding effects of multiple drugs and may contribute to
a common mechanism of addiction (Maldonado et al. 2006).
The VTA also contains many nicotinic acetylcholine
receptors (nAChR) by which nicotine triggers mesolimbic
dopamine release (Dani et al. 2005).
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The ECS has been studied extensively since the
characterization of a specific G-protein-coupled cannabi-
noid receptor in the rat brain (Devane et al. 1988). This type
1 cannabinoid receptor (CB1R) is expressed in high
concentrations in the brain and is preferentially distributed
at presynaptic neurons where it modulates the central
effects of cannabis and cannabinoid drugs and exerts its
effects by inhibition of the release of other neurotransmit-
ters, e.g., γ-aminobutyric acid, glutamate, and dopamine. A
second cannabinoid receptor, CB2, exists but is mainly
expressed in peripheral tissues, especially in cells of the
immune system. Different endogenous ligands, or endo-
cannabinoids, are known for these receptors. Anandamide
(AEA) and 2-arachidonoyl glycerol (2-AG) are the two best
characterized endogenous agonists (Di Marzo et al. 2004).
The association between cannabis and nicotine abuse is
known in humans through epidemiological, pharmacolog-
ical, and behavioral studies (Viveros et al. 2006). In rats,
nicotine and endocannabinoids seem to enhance the
reinforcing effects of both systems (Viveros et al. 2006),
and changes in endogenous cannabinoid levels have been
observed in different brain regions chronically exposed to
nicotine, such as the brainstem, hippocampus, cerebral
cortex, and striatum (Gonzalez et al. 2002). In mice,
administration of nicotine facilitates the pharmacological
responses, tolerance, and physical dependence induced by
Δ9-tetrahydrocannabinol (THC), the major psychoactive
component of Cannabis sativa (Valjent et al. 2002).
The CB1R may have an important role in the interplay
between the nicotinic system and the ECS. This receptor is
abundantly expressed in the cerebellum and in important
reward circuitry components among which are the VTA,
nucleus accumbens, amygdala, and hippocampus (Herkenham
et al. 1990). The rewarding effect of nicotine is reduced in
CB1R knockout mice (Castane et al. 2002), while CB1R
antagonists are able to reduce nicotine addiction, in rats but
also in humans (Cohen et al. 2002; Siu et al. 2007). In a self-
administration and a place conditioning paradigm in rats, it
has been shown that pretreatment with the CB1R inverse
agonist rimonabant decreased the response on the lever to
obtain intravenous nicotine infusions and the expression of a
conditioned place preference associated to nicotine, respec-
tively (Cohen et al. 2005).
In the present study, we evaluated possible alterations in
CB1R binding in the rat brain after daily chronic
administration of nicotine, using small-animal positron
emission tomography (PET) imaging and [18F]MK-9470
(N-[2-(3-cyano-phenyl)-3-(4-(2-[18F]fluorethoxy) phenyl)-
1-methylpropyl]-2-(5-methyl-2-pyridyloxy)-2-methyl prop-
anamide), a subtype-selective and high-affinity radioligand
for the CB1R (Burns et al. 2007). The primary objective was
to quantify potential direct pharmacological interactions
between nicotine and CB1R availability from a pathophysi-
ological viewpoint and assess potential bias by subject
smoking in human imaging studies (Van Laere et al. 2008).
Materials and Methods
Direct Binding Affinity
Direct binding affinity of nicotine at the CB1R was
evaluated in vitro using a competitive binding assay, as
previously described (Govaerts et al. 2004). Experiments
were conducted on membrane preparation from human
CB1R-transfected Chinese hamster ovarian cells (CHO-
CB1) incubated with 1 nM [3H]-SR141716A (Amersham,
Roosendaal, The Netherlands) and appropriate concentra-
tion of competition ligand. Nonspecific binding was
determined in the presence of 10 μM of the potent
cannabinoid agonist HU 210 ((+)-1,1-dimethylheptyl ana-
log of 7-hydroxy-delta-6-tetrahydrocannabinol; Tocris
Cookson, Bristol, UK).
Micro-PET Imaging
Twelve femaleWistar rats (body weight range 206–323 g; age
12 weeks; Charles River Laboratories France) were housed
three to a cage with food and water freely accessible in a 12-
h dark–light cycle (lights on from 8 a.m. to 8 p.m. daily). The
research protocol was approved by the local Animal Ethics
Committee and was according to the European Ethics
Committee guidelines (decree 86/609/EEC).
To induce the chronic condition, animals received a daily
intraperitoneal (IP) nicotine (n=6, 1 mg/kg, 1 ml) or 0.9%
saline (n=6, 1 ml) injection for 2 weeks. (−)-Nicotine
hydrogen tartrate salt (purity grade ≥98%, Sigma-Aldrich,
N5260) was used, dissolved in 0.9% saline. The saline-
treated rat data were used from similar pharmacological
interaction studies (Goffin et al. 2008; Casteels et al. 2010).
The dosage was chosen according to previous experiments
and its ability to affect endocannabinoid transmission
(Miksys et al. 2000; Gonzalez et al. 2002).
The precursor for [18F]MK-9470 was obtained from
Merck Research Laboratories (MRL, West Point, USA),
and labeling was performed by alkylation of the precursor
with 2-[18F]fluoroethyl bromide. Tracer preparation and
characteristics have been described previously (Burns et
al. 2007).
Animals were anesthetized for scanning with an IP
injection of 50 mg/kg sodium pentobarbital (Nembutal®,
CEVA Santé Animale, Brussels, Belgium). All rats were
fasted for at least 6 h prior to tracer administration and PET
imaging. An 18 MBq (500 μCi; mean=519±118 μCi;
injection volume 500 μL) [18F]MK-9470 radioligand was
administered via a tail vein. Specific activity of the tracer
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was always higher than 10 GBq/μmol at injection time.
Animals were imaged on day 1 in baseline condition and on
day 15 following daily nicotine or saline injections.
Small-animal PET imaging was performed on a Concorde
Focus 220 micro-PET (Siemens/Concorde Microsystems,
Knoxville, TN, USA) which has a transaxial resolution of
1.35 mm full width at half maximum. All data were acquired
in list mode in a 128×128×95 matrix with a pixel width of
0.475 mm and a slice thickness of 0.796 mm. Images were
acquired dynamically for 60min immediately following tracer
injection.
Scans were reconstructed using filtered back projec-
tion, and the last 20 min was used for measurement of
radioactivity concentration and quantification. As previ-
ously described (Casteels et al. 2006), all micro-PET
images were coregistered and spatially normalized to a
stereotactic space based upon the rat brain Paxinos atlas
(Paxinos et al. 1998). [18F]MK-9470 binding was estimat-
ed using parametric images based on standardized uptake
values (SUV), a unitless measure used to correct for
differences in injected dose and subject body weight,
making comparisons between subjects possible (SUV =
activity concentration (MBq/ml) × subject’s weight (g)/
injected dose (MBq); Burns et al. 2007).
Predefined volume-of-interest (VOI) and voxel-based
statistical parametric mapping (SPM2, Wellcome Depart-
ment of Imaging Neuroscience, London, UK) analyses
were performed. For VOI analysis, a predefined VOI
map was loaded on all parametric images to permit
calculation of average SUVs within each VOI as shown
in Fig. 2 (PMOD software, version 2.65; PMOD Inc.,
Zurich, Switzerland). The differences of chronic and
baseline SUV data (SUVdiff) were calculated for both
groups [((CHR−BL)×2)/(CHR+BL)], and these values
were compared with a Mann–Whitney U test (nonpara-
metric analysis of variance). Also, a univariate analysis
was done by comparing chronic to baseline SUV data
within each group with nonparametric Wilcoxon matched-
pairs tests (Statistica, version 6.1; StatSoft Inc., Tulsa,
OK, USA). Comparisons resulting in p values below 0.05
were considered significant.
For SPM analysis, data were smoothed with an isotropic
Gaussian kernel of 1.2 mm full width at half maximum.
Only significant clusters (p<0.05, corrected for multiple
comparisons) were retained, in combination with sufficient
localizing power (pheight<0.005, uncorrected for multiple
comparisons). The extent threshold kext was higher than 200
voxels (Casteels et al. 2006). For analysis of relative
receptor binding, activity normalization was done on total
cerebral counts using proportional scaling, and a relative
(gray matter) analysis threshold of 80% was set to exclude
extracerebral activity.
Results
A competitive binding assay demonstrated that the in vitro
direct binding affinity of nicotine at the CB1R was
negligible. Ligand displacement was 23.9±0.1% (mean ±
SD) and 21.7±1.3% at 10 and 100 μM nicotine, respec-
tively, which implies that the IC50 for nicotine is higher
than 100 μM.
The changes in [18F]MK-9470 binding between the
baseline and chronic condition, expressed as SUVdiff
values, were compared between the nicotine and the control
groups. No significant differences were found in SUVdiff
values of the nicotine and control group. The absolute mean
cerebral SUVdiff was 0.002 for the nicotine group and 0.042
for the sham group (p=0.94).
In a univariate analysis, chronic saline injections did not
produce any significant changes in [18F]MK-9470 binding
within this control group. The mean SUV value within the
cerebral VOI at baseline was 1.23 and 1.28 after 2 weeks of
saline administration (p=0.47; Fig. 1). In the nicotine-
treated rats, also no absolute changes in [18F]MK-9470
binding were found on a group basis (Fig. 1). The
intersubject variability (expressed as coefficient of variation
per VOI) of the absolute baseline measurements in both
Figure 1 Scatter plot of the
mean global gray matter (all
volume-of-interest regions)
standardized uptake values
(SUV) versus condition for the
six nicotine-treated rats (left)
and the six control (saline-
treated) rats (right). Horizontal
lines indicate the mean SUV in
each condition
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groups ranged from 5% to 20% (average coefficient of
variation = 14.8%).
Exploring regional changes within the nicotine group,
SPM analysis of relative [18F]MK-9470 binding showed a
small but significant increase in the chronic condition
compared to baseline in a cluster located in the left and
middle (vermis) cerebellum (Figs. 2 and 3). The peak voxel
difference was +6.8% (pheight<0.005 uncorrected, pcluster=
0.002 corrected) and located at Paxinos coordinates x=
−2.8 mm, y=−14.2 mm, z=−3.4 mm (x = lateral distance
from the brain midline; y = anteroposterior location relative
to Bregma; z = dorsoventral position; Table 1). VOI
analysis confirmed this finding with a significant relative
increase of average radioligand binding in a region of the
(bilateral) cerebellar volume of interest (125 mm³) of 1.8%
(p=0.041). No other areas of significant changes were
found on predefined VOI analysis.
Discussion
To our knowledge, in vivo data of CB1 receptor availability
changes due to nicotine exposure have not been previously
reported. Ex vivo studies showed an almost complete lack
of changes in mRNA levels or binding capacity of CB1R
following chronic nicotine exposure (Gonzalez et al. 2002;
Balerio et al. 2004). Gonzalez et al. found an increase in
endocannabinoid levels (AEA and/or 2-AG) in the limbic
forebrain and brainstem, while the hippocampus, cerebral
cortex, and striatum exhibited a decrease in endocannabi-
noid levels. No changes were seen in the cerebellum. In
contrast, significant changes in CB1 receptor protein levels,
quantified by Western blotting, were reported by Marco et
al. (2007). They observed increased hippocampal CB1R
expression and decreased striatal CB1R expression after
10 days of nicotine treatment, albeit in adolescent rats and
after a posttreatment interval of a month. In addition to the
evidence for increased effects of cannabinoids in adolescent
animals, the same may be true for nicotine. Nicotine in
adolescent, but not in adult male rats, produced changes in
cannabinoid receptors in specific brain regions (Werling et
al. 2009).
In the present study, the absolute SUV changes in the
nicotine group were not significantly different from the
changes observed after saline treatment. We found a modest
univariate increase of regional cerebellar CB1R binding
following chronic nicotine exposure. This change is
unlikely to result from a direct nicotinic effect onto the
CB1R, as we found no significant affinity of nicotine at
these receptors (IC50>100 μM), implying nicotine itself is
unable to displace the high-affinity [18F]MK-9470 radio-
ligand (rat IC50=0.9 nM) at the used dosage. As nicotine
has a half-life of 45 min in rat plasma, the last dose—
administered 24 h before the scan—was eliminated at the
time of PET scanning.
Therefore, indirect effects of chronic nicotine adminis-
tration on the ECS are most likely responsible for the
observed change by either modulation of endocannabinoids
or modulation of CB1 receptor density and/or affinity.
Previous studies have indicated that nicotine regionally
influences levels of endocannabinoids (Gonzalez et al.
2002; Maldonado et al. 2006; Marco et al. 2007) and
increases in anandamide can induce changes in cerebellar
CB1 receptor binding, probably through changes in
receptor density (Romero et al. 1995). After chronic
exposure to this endogenous agonist, the binding capacity
of CB1 receptors in the cerebellum and hippocampus
increases, while these receptors remained unaffected in
other brain regions (Romero et al. 1995). Other findings
also support this regional dependence of cannabinoid
receptor response to agonists, such as the regionally and
treatment-dependent CB1R downregulation elicited by
administration of the exogenous CB1R agonists THC and
WIN 55,212-2 (Sim-Selley et al. 2002).
The cerebellum is a brain region with a high density of
CB1 receptors and nicotinic acetylcholine receptors, the
latter mostly containing alpha7 or alpha4 and beta2
subunits (Herkenham et al. 1990; Reno et al. 2004). By
stimulating alpha7-nAChRs, nicotine induces enhanced
glutamate release, resulting in increased cerebellar oxida-
tive stress (Reno et al. 2004). It can be hypothesized that, in
view of the homeostatic nature of the endocannabinoid
system and its ability to downregulate cerebellar glutamate
release (Breivogel et al. 2004), the obtained CB1R
upregulation could be an attempt to counteract this
increased glutamatergic neurotransmission and reestablish
baseline neurotransmission levels.
Figure 2 Micro-PET mean images of nicotine-treated rats visualizing
[18F]MK-9470 binding per condition expressed in standardized uptake
values (SUV). The spatially normalized MRI template and the overlaid
volume-of-interest map are shown in the right column and upper row,
respectively
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The area-under-the-curve SUV macroparameter is a
good index of CB1R binding at the measured scanning
interval, as indicated by modeling studies of tracer kinetics
(Burns et al. 2007; Sanabria-Bohórquez et al. 2010; Terry et
al. 2009). Possible increases in regional cerebral blood flow
(CBF) induced by nicotine as documented by brain imaging
studies in humans (Rose et al. 2007) could theoretically
augment the tracer delivery to the brain. We have
empirically observed only minimal effects of CBF changes
on the SUV macroparameter using IV acetazolamide at
concentrations that induce up to 70% CBF increases in the
rat brain (unpublished results). Therefore, possible CBF
changes are unlikely to have confounded our results.
Nicotine-treated animals show a higher intersubject
variability in CB1R availability measurements compared
to saline-treated animals, at baseline as well as after the
treatment period. Possible reasons for this cannot be
obviously inferred from this experiment; however, some
factors should be taken into consideration. Firstly, despite
all animals being female, it is possible that the hormonal
status of the animals differs between both groups and that
this difference influences radioligand uptake. Secondly,
data from the saline rats, as a historical control group, were
acquired in an identical experimental setting but at a
different time. Finally, increasing the number of subjects
per group could be a way to reduce intersubject variability
in future studies.
As this study has only addressed the pharmacological
effect of nicotine administration on [18F]MK-9470 binding
at the CB1R and rewarding effects of smoking are not fully
reproducible in this animal model, our results do not
exclude a possible role of the CB1R and ECS in tobacco-
induced nicotine addiction.
In conclusion, administration of nicotine does not alter
the in vivo CB1R availability in the rat cerebrum measured
with [18F]MK-9470, and only a modest regional CB1R
binding increase was found in the cerebellum. From a
translational point of view, this study suggests that chronic
Table 1 p values and locations of the significant clusters in the comparison of the relative CB1R availability in the chronic condition versus the
baseline condition in nicotine-treated rats
Chronic > baseline
Cluster level Voxel level Structure
pcorr kE puncorr T puncorr x y z
0.002 591 <0.0001 14.94 <0.005 −2.8 −14.2 −3.4 Left cerebellar hemisphere
11.64 <0.005 −3.2 −13.2 −4.0
11.63 <0.005 −5.2 −12.6 −4.0
kE cluster extent, x lateral distance in millimeter from the midline (a negative value indicates a localization on the left side), y anteroposterior
location relative to Bregma (negative values indicate spots posterior to Bregma), z dorsoventral position (based upon the Paxinos stereotactic atlas)
Figure 3 a Orthogonal section with SPM T-map for the relative
difference in [18F]MK-9470 binding after chronic nicotine injection
rendered on the MRI atlas of the rat brain in Paxinos space (L = left;
R = right). T values are indicated by the color bar. b Change (in
percentage) of the relative standardized uptake values (SUV) at the
maximal peak location in the cerebellum after chronic nicotine
administration for each rat. The mean value of increase in the chronic
condition is indicated by the horizontal line
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nicotine usage is unlikely to interfere with in vivo CB1R
binding of [18F]MK-9470 in human studies, although direct
confirmation in humans is needed.
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